Note: Descriptions are shown in the official language in which they were submitted.
WO 99126939 PCT/IB98/0191Z
-1-
INTERMEDIATES AND METHODS USEFUL IN THE
SEMISYNTHESIS OF PACLITAXEL AND ANALOGS
TECHNICAL i=IELD
The present invention relates to semisynthesis of paclitaxel and its analogs
using new intermediates which are derivatives of 10-deacetyl-baccatine III, as
well
as to a method for preparing these derivatives. These novel derivatives have
carbonate substituents in the 7 position, such as t-butoxy-carbonate.
BACKGROUND ART
Paclitaxel, a well known potent antitumor compound having a broad
spectrum of antitumor activities, has the following structure of formula (I):
OH
o _. Il
O 1p .7
~ Nli O / ~ 1 2
2' ,O HO O
/ off o
o~
Commercial pharmaceutical products containing this compound are
available, e.g., for treating ovarian and breast cancer in women. For these
reasons, greater and greater supplies of this compound are required each year.
Pacl'ttaxel and baccatine III are extracted with difficulty and in general in
low yields
from the trunk barks of different Taxus species. Thus, alternative sources of
this
compound are necessary.
CA 02310778 2000-OS-18
CA 02310778 2003-12-17
r::: ' -2-
Several synthetic rnethads have been reported both in scientific and patent
literature. U:S, patent RE-34,2?7 (a reissua of U.S. patent 4,924,01 1~
discloses
the semisynthesis of paciitaxef using a 'I O-deacety!-baeeatine Ill derivative
which
is protected in the 7 position with a tri-alkyl-siiyf group which is
speoifiically~
shown as a tri-ethyl-silyl ("TES") group and which is also protected m the 10
position with an acetyl group. This baccatine tit derivative is allowed to
react with
. a t2R,SSA-N-benzoyl-2-0-('1-ethoxyethylf-3-phenyl-isoserine cvrr~pound
before
removal of the protecting groups to obtain the paclitaxel.
In PCT application WO-9~106Q94, paclitaxel was prepared by reacting a
side chain precursor of a ,~-lectarn compound with 7-0-TES-baccatine 111
derivative
to provide a 7-TFS-baccatin il! reaction product. After a mild aCidiC post-
reaction
treatment, paclitaxei was obtained.
In U.S. patent 5,476,954, the synthesis of paciitaxel was conducted
starting from a protected 10-deacetyi-baccatine !ll derivative that contained
a
2, 2, 2-tri-chfvrvethoxy-carbonyl (,"TRC~C") pr otective gro~rp in both the 7
ana 't 0
positions of the derivative.
CA 02310778 2003-12-17
' -ZA-
EP 0 61 ~ 034 discloses a process to form 2-debenzoyt-2-acyt taxol*
derivatives. tn the disclosed process, C-13-substituted, 2-benzoyt taxot
analogues
in which the C-7 and C-10 hydroxyl groups are protected with various
protecting
groups inctuding '60C, are setective(y deprotected and re-acyiated at the C-2
position to form tE~e ~-debenzayt-Z-acyt analogues.
1Na 94/07879 discloses a method for preparing taxane derivatives by
esterification of a protected baccatine tti or 10-deacetytbaccatine ttt using
an
oxaZOtidine acid. The baccatine starting materials are preferably protected at
the
C7-position with a trichtoroethyt carbonyl or a trichioroprapyi carbonyl
radical.
EP 0735 036 discloses a method far the preparation of taxanes using
substituted oxaxolidines. in the disclosed procedure, C-t 3-substituted
taxanes are
prepared by reacting the oxazotidines with a taxane moiety which is protected
using variflus protecting groups, Ths C-7 hydroxyl group of the taxane moiety
is
praferabty protected with triaikyisi(yf.
it is welt known that the key step in the samisynthesis of pactitaxet is to
setectivefy protest the 7 position with a leaving group that Gan be Easily
removed.
This is because the hydroxy group in that position of the taxane structure is
much
more reactive than those in position 9 p or 13, and the pactitaxet product to
be
synthesized needs to have a hydroxy group in that position. Unfit now_,
however,
the mast useful protecting group was considered to be TES. The derivatization
yield of 10-deacetyt-baccatine fit with TES is typically about 85% ~nyen 2Q
motes
of the reagent are used. Ths acetyiation step, using 5 equivalents of
acetylchtoride, provides about 85a/c of 7-TES-baccatine ttt. as per the
teachings of
PCT application Wa-93106094 and its U.S, equava(ent documents such as U.S.
i'atent 5,574,1 ~~.
* Trade-mark
W .v. . - . ~~ ..._.' _ ._. ~i~ v ' _~~w ~ V1~1 Va7V VvVi~ t
.. _ _. __. .. _._ _ .. Ta oa s.am~r~ruo:_ir ~
_3-
In view of the importance of paclitaxel, however, new and improved methods for
its prodvotion are desirable,
The present invention provides such improved syntheses of paciitsxel end
its analogs primarily using new derivatives of 10-deacetyl-becoetin Ill as
intermediates,
SUMMARY Ol= THE INVENTION
The present invention relatos to an intermediate for use in the semisynthesis
of paciltaxel, comprlsfng a compound of formula tlt):
a
A
rll.r
~H4C00 -
AG4
wherein:
A is CHa
i
--C-O-'C CHI
CH3
R, Is a hydraxy-protecting group or a hydrogen atom; and
R~ is a hydroxy-prot~eting group selected from the group aonsieting of C,,~
carboxylic acid aryl groups (such as acetyl), trialkylsilyl groups, wherein ;
each alkyl group contains 1-3 carbon gtorns, and the group A as defined
above; or a hydrogen atom.
CA 02310778 2000-OS-18
WO 99/26939 PCTlIB98101912
-4-
Examples of hydroxy-protecting groups include C~.~ carboxylic acid acyl
groups, for example acetyl, trialkylsilyl groups wherein each alkyl group
contains
1 to 3 carbon atoms and the group A defined above, e.g. a t-butoxycarbonyl
group
of formula ~ CH3
0
C 'p C CH3
CH3
Preferably, therefore Rl is a C,.~ carboxylic acid acyl group, for example
acetyl, a trialkylsilyl group wherein each alkyl group contains 1 to 3 carbon
atoms
or the group A defined above, e.g. a t-butoxycarbonyl group
R2 may be any of these groups, but because the 13-hydroxy group is less
reactive, protection is not essential, so RZ can conveniently be hydrogen.
During the semisynthesis of paclitaxel, an N-benzoyl (2R, 3S)-3-
phenylisoserine group is introduced at the 13-position of an appropriately
protected
derivative of baccatine III. The resulting protected derivatives of paclitaxel
have the
general formula Ills)
RIO
~l _ 0-A
g~.o""~ , ,
,,
cll
C6H5C00
ACO ~ O
wherein A is
CH$
- G~--0-C CH3
CHI
R, is a hydroxy-protecting group or a hydrogen atom; and
CA 02310778 2000-OS-18
w.v.. ,. _.- _..-'_:u~~~_w._y ~~.~a=.~.-._~-~_.10,JV ~ Vll1 GJV V11V1~_..
T1_t~ t32.'~~i~tl~Y~'!~bD:i1
a - -
RZ, is a (2R,3S1-3-phenylisoserine derivative having the structure:
~"~~3
CsHsCONH
GO~-
~8H5
where R~ is a hydroxy-protecting group, such as A (as defined above), a
methoxy
I methyl, 1-ethoxyethyl, benzyloxymethyl, ,B-triaikylsilylethoxy)methyl where
each
alkyl group contains 1 to 3 carbon atoms, tetrahydropyranyl or
2,2,2-trichloroethoxycarbonyl group; or a hydrogen atom.
The inv~ntion further relates to a process for producing paclitaxel by the
steps of forming the intermediate campound of formula ills) and removing the A
and R9 groups to form paclitaxel.
For the preparation of compounds of formula If and f la where R, is acetyl the
process of the invention preferably comprises forming the intermedietc
compound
i) by reacting 10-deacetylbaccatine III with a reagent capable of introducing
a t-
butoxycarbonyl group, for example t-butoxy-pyrocarbonate to obtain
7-t-butoxycarbonyl-10-deacetyl baccatine III. The thus obtained
7-t-butoxycarbonyi-10-deacetyl baccatine III may then be acetylated to obtain
7-t-butoxycarbonyl-baccatine III.
10-Dsacetylbaccatine I1E is highly insoluble in most common solvents and
accordingly the choice of solvent is important in order to ensure that the
reaction
in which the t-butoxycarbonyl group is introduced proceeds at en acceptable
rate
and in high yields. Thus, for example, 10-deacetyl is highly insoluble in
methylene
dichloride. If methylene dichloride is used as a solvent for the reaction of
10-
deacetyibaccatine with t-butoxypyrocarbonate see, e.g. Example 1 below), the
CA 02310778 2000-OS-18
WO 99126939 PCT/IB98/01912
-6-
reaction proceeds at a reasonably fast rate on a small scale, but when
operated on
a large scale, the reaction can be unacceptably slow. -
On the other hand, if a polar aprotic nitrogen-containing solvent such as
pyridine is used for carrying out the reaction (see Example 8 below) the
reaction
proceeds more rapidly, but the yield can be lower as a result of formation of
7,10-
di(t-butoxycarbonyl) baccatin as a by-product.
Although there may be a minor penalty in terms of lower yield, the use of
pyridine as a solvent has advantages on the industrial scale in view of the
higher
rate of the reaction. Also it is possible to carry out the next step in the
process,
i.e. the introduction of an acetyl group in the 10-position, without
separating or
purifying the desired 7-t-butoxycarbonyl 10-deacetylbaccatin. Le. the reaction
in
which the t-butoxycarbonyl group is introduced and the acetylation reaction
can be
carried out in one pot.
Further, if the starting material is in the amorphous (anhydrous) form the
reaction proceeds more rapidly than if the starting material is in the form of
the
crystalline hemihydrate.
The hydroxy group in position 13 of the 7-t-butoxy- carbonyl baccatine III
may then be converted to a (2R,3S)-3-phenylisoserine group having the
structure
O R~
CBHSCONH
'CO-
CgHS
wherein R3 is hydrogen by reaching the 7-t-butoxy-carbonyl-baccatine III with
an
oxazolidine derivative of formula 1111)
CA 02310778 2000-OS-18
l\ ~r I . . -. -~ ~- - - - . -- ~ .. . . . ~ -. -. - .. . .~ V 1 1 i V V V V V
V i - - . - - = V =.= -r V V V'i ~' V V ~ 11 V
R4 C02H
-,N O
RS-C
11.
Rs
wherein R' is an aryl group or a straight or branched chain alkyl or aikenyi
group
having 1-5 carbon atoms; and Ra is R,, or a t-butoxy group, end aech of Rs and
R~
is a halogenated methyl group. Advantageously, an excess of the
7-t-but~xy-carbonyl-baccatine Itl compound is used relative to the oxazolidine
( derivative.
The oxazotidine derivatives of formula (III)
COzH
~,N O
Ra-C
Ii
O Rs Rr
where R" R$, RB and R~ are as defined above from a further aspect of tha
present
invention. Preferably, R~ is phenyl, Rs is phenyl or a t-butoxy group, and
each of
I RB and R~ is a CICH2-, BrCHz- or FCC- group.
The oxazolidine derivatives of Formula III may be prepared by reacting a
compound of Formula iV with a ketone of formula RaR~ CO (V)
R4 OORB
(IV)
NFi ~H
R CO
a
In formula tV and V R4, R~, Ra and R, are as defined above, end R8 is a
residue of an alcohol Re OH in whit Re is, e.g, a C,_4 alkyl group, e.g.
methyl.
CA 02310778 2000-OS-18
WO 99/26939 PCT/1B98101912
-g_
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides novel methods for the semisynthesis of
paclitaxei of the general formula (I) given above through the use of the new
intermediates of formulae (II) and (11a). These new intermediates are
versatile
intermediates which also can be used for the semisynthesis of docetaxel and
other
analogs of paclitaxel. The process for their preparation is also described.
It has been found, surprisingly, that protecting the hydroxy group at position
7 .of 10-deacetylbaccatine III or similar taxane derivatives with the same
basic
structure, with certain carbonate compounds provides enhancements in the
preparation of paclitaxel from such derivatives.
A preferred protective group is t-butoxy-pyrocarbonate (BOC):
CH3
O C CH3
CH3
This protective group can be substituted in position 7 and, if desired, as
well as
in position 10.
As position 10 is not as reactive as position 7, a number of other protective
groups can be used in position 10. In particular, the group -ORS can be used,
where R~ is a hydroxy-protecting group or a hydrogen atom. Any of a wide
variety
of hydroxy-protecting groups can be used, including the carbonate groups
described above for A, the G~ groups of the compounds of formula III of U.S.
Patents 5,578,739 or 5,621,121, the Rz groups of the compounds of formula III
CA 02310778 2000-OS-18
CA 02310778 2003-12-17 -
of U.S. patent 5,476,954, or the R3 suostituents of the compounds of formula
(V
of ll.S. patent Re. 3~, 277.
It is possible to obtain almost quantitative yields of the 7-BOC-10-
deacetylbaccatine !It derivative from 10-deacetylbaccatine tli. The BOG
protecting
group is easily and selectively removed in very mild acidic conditions using a
catalytic
amount of mineral or organic acids, preferably formic or F3C-COOH.
The synthesis of 7~BOC-7 ~-deacetylbaccatine Ill or its analog may be
perfvrrned in chlorinated solvents, preferably in methylene chloride using
dimethyiformamide as a co-solvent. 1 Mole of 10-deacetyl-baccatine Iii or the
ci~ose:~ taxana anaicg rnay be reacted with 7 ,2 to 2.5 equivalents
t-terbutoxy-pyrocarbonate in the presence of 7.2 equivalents of
ethyldiisapropylamine anti a catalytic amount of 4-dirr~ethylaminopyridine.
Under
these conditions, it is possible to obtain in almost quantitative yields the 7-
BOC-
derivative. This compound can be corivert2d into 7-l3OC-? 4-acetyl
derivati~,~e using
acetyl chloride, bromide or diketane as shown in the exampEes.
These derivatives can then be converted to biologically active compounds
by estertfying the hydr oxy group at the 13 position v~rith an axa~olidine
derivative
o~ -formula (~!!~:
GOZH
I
0
O Rs R7
vvi:ereir: R,~ is an ary) group or a straight or branched chain alkyl or
alicenyt group
having 1-5 carbon atoms; and R5 is Rø or a t-butoxy group, and each of R6 and
R~
is a halogenated methyl group.
CA 02310778 2003-12-17
WO 99/26939 PCT/IB98141912
- 10-
The reaction is generally performed in aprotic solvents, preferably benzene,
toluene, xyfene, chforobenzene ar ethyfbenzene, preferably in the presence-of
a
condensing agent such as dicyclohexyfcarbodiimmide (DCC? and a catalytic
amount
of a base such es dialkyiamino pyridine, preferably 4-dimethylaminopyridine at
temperatures ranging from about 50°C to 100°C, and preferably
70°C.
Preferably, to obtain the desired compounds, 4 Moles of condensing agent
and 1.5 Mole of the oxazolidine derivative are used for 1 Mole of protected
taxane.
After elirriination of the reaction byproducts and the solvent, the 13-ester
may be
isolated in crude form. This compound may then be treated in methanol with a
catalytic amount of anhydrous HCl at room temperature or at temperatures
ranging
from about 5°C to 10°C, and preferably at 0°C, with
concentrated formic acid
(98%) until complete deprotection of the BOC group at the 7 position and of
the
protective group R3 of the side chain at position 13 is achieved. After
treatment
of the reaction mixture with brine, the taxane derivative may be extracted
with a
solvent that is non-miscible with water, and preferably with ethylacetate.
After
distillation of the extraction solvent, the taxane derivatives may directly be
crystallized with suitable solvents or subjected to chromatographic process
using
silica-gel and as eluting solvents, a mixture preferably constituted by
hexane/ethylacetate in a suitable ratio.
Alternatively, paclitaxel and its analogs can be prepared by esterifying the
protected baccatine with a phenylisoserine chain esterified at 2 position with
BOC.
The reaction conditions described above for the reaction using a oxazolidine
derivative may be used.
The hydroxy group at position 13 can be esterified in a number of other
ways as disclosed, e.g., in U.S. patents 5,578,739, 5,574,'156, 5; 621,121,
5,476,954, 5,470,866, 4,857,653, 4,814,470, and Re. 34,277, and in European
Patent Application 0,525,589-A1.
WO 99126939 PCT/IB98J01912
-11-
EXAMPLES
The examples below alre reported, without implied limitation, to show how
the invention can be put in practice.
Example 1: Synthesis of 7-~,OC-10-deacetyfbaccatine III.
A 500 mg sample of 1j0-deacetylbaccatine ill (0.92 mMo!) was suspended
in CHZCIZ (5 mL) and ethyldiisopropylammine ( 1.10 mMol, 1.2 Equiv.),
t-butoxypyrocarbonate (2A+0 mg, 1.10 mMol, 1.2 Equiv.) and DMAP
(4-dimethylaminopyridine, 20 mg) were added.
The reaction was stirred 48 h at room temperature and then additioned with
the same quantity of reagenlts and allowed to stay under stirring per other 48
h.
The reaction was worked upj by dilution with CH2CI2 washing with HCI and
brine.
After drying, 580 mg of 7-B~c- 10-deacetylbaccatine III were obtained having
the
following characteristics: m~ 148°C and 162°C; 1 H-NMR 200 Mhz,
CDCI3, TMS
as internal standard; Bz 8.'10, br d, J 8; Bz 7.70, br t J 8; Bz 7.55, br t J
8;
H2, 5.64 d J 7; H10, 5.54, s; H7, 5.36, dd, J 11.0, 8.0; H5, 4.95, d J 8; H13,
4.91, br t, J7.5; H20a, 4.3j2 d, J 8.0; H20b 4.26, d, J 8.0; H3, 4.09 d, J
8.8;
Ac. 2.29 s; H 18 2.09 s; H 19 1.83 s; Boc 1.46 s; H 16 1.34 s; H 17 1.20 s; IR
(KBr) 3480 (OH), 1740 (br, IC = O), 1603, 1371, 1275, 1259, 1158, 1092, 712.
Example 2: Synthesis of 7-'BOC-10-deacetylbaccatine 111
A 500 mg sample of '10-deacetylbaccatine III (0.92 mMol) was solubilized
in 1 ml of dimethylformamide and diluted with 4 ml of CH2CI2. The reagents and
the reaction conditions are ithe same of Example I.
CA 02310778 2000-OS-18
WO 99/26939 PCTIIB98/01912
-12-
Example 3: Synthesis of 7-BOC-baccatine 111.
644 mg (1 mMol) of 7-Boc-10-deacetylbaccatine III prepared according to
example 1 or 2 ware dissolved in 5 mL of pyridine and at 0°C under
stirring 1.2
g of acetylchloride were added ( 15 mMol) in 15 h. When the reaction is
finished
the solution is diluted with CHZCI2 under stirring and washed with 60 mL of
H20.
The organic phase is washed several times with HZO and diluted HCI until the
elimination of pyridine. The solvent dried on NaZS04 is evaporated under
vacuum
and the residue crystallized from hexane/acetone. 660 mg of 7-Boc-baccatine
III
were obtained having the following characteristics: mp 190-97°C. 1 H-
NMR 200
Mhz, CDCI3, TMS as internal standard; Bz 8.10 br d, J 8; Bz 7.70 br t, J 8; Bz
7.55, br t J 8; HZ, 5.64 d, J 7; H10, 5.52 s; H7, 5.44 dd, J 10.3, 7.0; H5,
4.98,
d, J 7.9; H13, 4.50 br t; H20a, 4.32 d, J 8.0; HZOb 4.22 d, J 8.0; H3, 4.02 d,
J
6.7; Ac. 2.30 s; H 18 2.19 s; Ac. 2.16 s; H 19 1.80 s; Boc 1.48 s; H 16 1.17
s;
H 17 1.07 s.
Example 4: Synthesis of paclitaxel.
1.65 gr of (4S,5R)-2,2 -di(chloromethyl)-4-phenyl-N-benzoyl-5-oxazolidine
acid were allowed to react in toluene with 0.69 gr of 7-Boc-baccatine III in
the
presence of 1.1 Equival. of DCC and 60 mg of 4-dimethylaminopyridine. The
reaction mixture was maintained at 60°C for 12h under stirring in Argon
atmosphere.
At the end of the reaction (TLC) the reaction mixture was filtered form
insoluble byproducts and the solvent washed with H20 and distilled under
vacuum.
The residue is solubilized in 10 mL of conc. formic acid at 0°C and
kept in this
condition for 2h. The reaction mixture was diluted with 100 mL of H20 and
cloudy solution extracted three times with 50 mL CH2C12. The organic phase was
washed with a solution of NaHC03 and then with H20. The organic phase after
drying on Na2S0,, is concentrated under vacuum. The residue was
CA 02310778 2000-OS-18
WO 99/26939 PCTnB98/0191Z
-13-
crystallized from ethanol/water and 0.81 gr of paclitaxel having the well
known
characteristics which have been reported in the literature was obtained.
Example 5: Reaction of 10-deacetylbaccatin III with Boc-pyrocarbonate
A 500 mg sample of 10-deacetylbaccatin III (0.92 mMol) was suspended in
CH2CI2 (5 mL) and ethyldiisopropylamine (190 NL, 1.10 mMol, 1.2 mol. Equiv.),
BOC-pyrocarbonate (240 mg, 1.10 mMol, 1.2 mol. Equiv) and DMAP (4-
dimethylaminopyridine, 20 mg) were added. The reaction was stirred 48 h at
room
temp, and then further BOC-pyrocarbonate (240 mg, 1.10 mMol, overall 2.4 mol
equiv.) and ethyldiisopropylamine (190 NL, 1.10 mMol, overall 2.4 mol ,
equiv.)
were added. After stirring for an additional 120 hours, the reaction was
worked
up by dilution with CHZCI2, washing with HCI and brine. After drying the
residue
was purified by column chromatography (ca. 5 g silica gel). Elution with
hexane-
EtOAc 6:4 gave 327 mg BOC DAB (yield: 55°6 conversion:
92°~) Elution with
ETOAc gave 195 mg recovered DAB.
Example 6 - Reaction of 10-deacetylbaccatin III With BOC-ON
To a solution of 10-deacetylbaccatin III (400 mg, 0.73 mmol) in pyridine (3
mL), BOC-ON [ = 2-(tart-butoxycarbonyloxiymino)2-phenylacetonitrilel - (543
mg,
2.19 mmol, 3 mol. equiv.) and 4-dimethylaminopyridine (90 mg, 0.73 mmol, 1
mol.equiv) were added.
The reaction was followed by TLC (hexane-EtOAc 4:6, Rf starting material:
0.1; Rf 7-BOC derivative 0.50; Rf 7,10-diBOC derivative: 0.56). After stirring
at room temp. for 10 days, the reaction was worked up by dilution with water
and
extraction with chloroform. After washing with sat. citric acid, sat. NaHC03
and
brine, the, solution was dried (MgS04) and evaporated, to afford a semi-solid
residue (1.07 g). The latter, when analyzed by'H NMR spectroscopy (200 MHz),
turned out to contain the 7-BOC and the 7,10-diBOC derivatives in a 85:15
ratio.
CA 02310778 2000-OS-18
WO 99/26939 PCT/IB98/0191Z
-14-
Purification by column chromatography (hexane-EtOAc 6:4) afforded 265 mg of 7-
BOC -10-deacetylbaccatin III (yield: 5696). -
Analysis - 7 BOC-10-deactylbaccatin III
Wh'tte powder, mp 162 °C;
IR (KBr): 3480, 1740, 1603, 1371, 1275, 1259, 1158, 1092, 712
CI-MS: 645 (M + H), C34H44012
1H NMR (200 MHz, CDCI3) : 8.10 Ibr d, J = 8.0 Hz, Bz); 7.70 Ibr t, J = 8.0 Hz,
Bz) .
7.55 (br t, J = 8.0 Hz, Bz), 5.64 Id, J = 7.0 Hz, H-2), 5.54 (s, H-10), 5.36
(dd,
J = 11.0, 8.0 Hz, H-7), 4.95 (d, J = 8.0 Hz, H-5), 4.91 (br t, J = 7.5 Hz, H-
13),
4.32
(d, J = 8.0 Hz, H-20a), 4.26 (d, J = 8.0 Hz, H-20b), 4.09 (d. J = 8.0 Hz, H-
3),
2.29
(s, OAc), 2.09 (br s, H-18), 1.83 (s, H-19), 1.46 (s, BOC), 1.34 (s, H-16),
1.20 (s,
H-17).
Analysis - 7-BOC-baccatin III
White powder, mp 197 °C;
IR (KBr): 3580, 3497,1750,1724,1713,1273;1240,1070,980.
M.W.:686, C38H48~13
1H NMR (200 MHz, CDCI3): 8.10 Ibr d, J= 8.0 Hz, Bz );7:70 (br t, J = 8.0 Hz,
Bz).
7.55 (br t, J = 8.0 Hz, Bzl, 6.52 (s, H-10), 5.64 (d, J = 7.0 Hz, H-2), 5.41
(dd,
J =11.0, 8.0 Hz, H-7), 4.98 (d, J = 8.0 Hz, H-5), 4.90 lbr t, J = 7.5 Hz, H-
2), 4.32
(d, J = 8.0 Hz, H-20a), 4.22 (d, J = 8.0 Hz, H-20b), 4.02 (d,J = 7.0 Hz, H-3),
2.30
(s, OAc), 2.19 (br s, H-18), 2.16 (s, OAc), 1.80 (s, H-19), 1.48 (s, BOC),
1.17 (s,
H-16), 1.07 (s, H-17).
CA 02310778 2000-OS-18
CA 02310778 2003-03-26
WO 99126939 PCT/IB98/01912
-15-
Example 7 - Preparation of Dichlorooxazolidine Derivative Illa
(Methyl Ester of Compound of Formula III with
RQ = R5 = phenyl; R6 = R~ =-CHZCI)
500 mg of N-benzoyl-phenyl-isoserine methylester in 30m1 of
tetrahydrofuran/benzene 1:1 mixture was allowed to react with 1 g of
dichioroacetone and 50 mg of PTSA (pyridinium p-toluenesulfonate) in the
presence
of a molecular sieve (3A,). The reaction mixture was heated and refluxed for 2
days. At the end of the reaction, the residue was washed with hexane in order
to
eliminate the excess of dichloroacetone.
The residue in 20m1 of MeOH was mixed with 220 mg of K2C03 in 20m1 of
H20. After 2 hours, methanol was evaporated under vacuum and the aqueous
phase was acidified with a 5% solution of KHS04 and then extracted with
ethylacetate.
The obtained acid was used then used directly for the esterification of 7-Boc-
acetylbaccatine 111 (see Example 4).
Example 8 - Reaction of 10-Deacetylbaccatin III with Boc-Pyrocarbonate
BOCZO (800 mg, 37 mMol, 2 mol. equiv.) and DMAP (220 mg, 18.5 mMol,
1 mol. equiv.) were added to a solution of 10-deacetylbaccatin Ill (1.0 g,
18.5
mMol) in pyridine (15 mL), . The reaction was followed by TLC (hexane-EtOAc
f:6, Rf st.m = 0.10; Rf7-boc-derivative 0.50; Rf 7,10-diBOC derivative: 0.56).
After stirring (16 h at room temp.), the reaction mixture was cooled to
0°C,
and AcCI (261 ,uL, 37 mMol, 2 mol. equiv.) was added. The reaction was
followed
by TLC (1,2-dichloroethane-EtOH 96:4 x 4).
After stirring at 0°C for 5 h, two further equivalents of AcCI were
added,
and stirring is continued at 0° for a further 2 hours. The reaction
mixture was
then worked up by addition of water (ca 150 mL) to the reaction flask. After
30
WO 99/26939 PCT/IB98J01912
- 16-
min. water was decanted from the reaction flask, and the sticky precipitate on
the
walls of the was taken up in EtOAc (30 mL), washed with dil HCI (10 mL) and
brine ( 10 mL1. After drying (MgS04) and evaporation of the solvent, 1.18 g of
a
yellow powder are obtained. When analyzed by NMR, the product was a 82:18
mixture of 7-BOC baccatin III and 7,10-diBOC baccatin Ili.
CA 02310778 2000-OS-18
